We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dinoken,
Whilst we may be first to be approved, it was with a label limitation and Merck's Keytruda is vying to be the first-line treatment of choice for endometrial cancer.
https://www.fiercepharma.com/pharma/gsk-beats-merck-first-pd-1-approval-newly-diagnosed-endometrial-cancer
SP is ridiculously cheap v peers.
All IMHO DYOR
Happy
The MMs have this by the throat - look a Auto-Ex trades pinning SP down ; more than 500 trades before 9am?
Who buys/sells 1 or 2 shares at below BID?...MM magic algorithm nos. today are 223, 228 & 239
Jemperli plus chemotherapy approved by US FDA as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population. Great result for GSK Oncology.
Oh no. Tipped by Motley Fool. Either caused yesterdays malaise or sparked todays rise ...
Probably that 1B increase in net debt doesn't convince the market, who knows ...
Reaction to my post? Now it is DOWN on the day!!!
Figures better than 'not bad' yet sp barely p%ositive, Why? Because its GSK of course. Deserves at least 1%.
I fully agree. The sooner its settled the better.
IMO Rerate awaits Zantac anchor cut away.
Consensus beat again.
Turnover. £7.2bn vs £6.8bn
EPS. 40.1p vs 34.7p
All they can do is to continue to beat consensus, develop the pipeline, and eventually that re-rate will come.
Wow, half expected concensus beaten but did not see increased future guidance. Should be a good day !
So do I, but sadly this has historically not lifted the sp. Hoping for best ...
Consensus estimate: Earnings of $0.85 per share, down 2.3% from Q2 last year. Revenue $8.49bn, down 2.5%.
GSK has beaten the consensus earnings per share number in each of the last four quarters. I think they will do it again.
Back in
GSK were the first to get FDA approval for RSV closely followed by Pfizer ( ABRYSVO ). AZN / Sanofi have a treatment to protect babies from the virus, multiple shots at the market. GSK vaccine is for patients over 60 years of age. Time will tell who gets what share of the market, hence the cool response to the news imo. DYOR
From the good news article,
"The Medicines and Healthcare products Regulatory Agency (MHRA) has approved GSK’s jab, known as Arexvy, for use among older adults.
It comes after a trial showed the jab had a high level of efficacy and that the vaccine is generally well tolerated.
Neale Belson, senior vice president, and UK general manager at GSK said: “We are very excited by today’s announcement.""
Good news link.
[LINK REMOVED]
[LINK REMOVED]
theguardian.com/society/2023/jul/10/rsv-vaccine-respiratory-syncytial-virus-older-adults-approved-uk-medicines-regulator
Great news.
[LINK REMOVED]
Maybe 1200. But I've had GSK for over 5 years and seen this go between 1200 and 1800 like a yoyo. I've set a ridiculous target of 2000 to let me collect dividend income.
Looks like 1300 didn’t do it. Next stop 1200……
Dunno ...I think is a great defensive stock and given the times we live in, I rather hedge my bets here than US stocks for example, Inflation won't stay around forever, these are great times to fill your boots IMHO
TerryMC1 and RonnieH contribute doom and gloom on numerous BB's, 407 posts in the last 30 days between them. Check out their posting history, pathetic delusional traders.
It is precisely for times like these that I keep cash on standby. Chewise is right. This a buying opportunity and we should be grateful these come along from time to time. GSK, LGEN, NG, DGE and a whole bunch of other FTSE giants are well down right now and all pay divs and all will recover one day, but maybe not Vodafone, If you don't like it, check the amall print where it says you might not get your money back and put your monry in the post office instead.
Ive put a limit buy at 1200, my hunch tells me thats about right.... but what would I know ! :) gla